Skip to main content
Advertisement
Advertisement

FATE

FATE logo

Fate Therapeutics, Inc.

2.34
USD
Sponsored
+0.03
+1.30%
Sep 14, 15:59 UTC -4
Closed
exchange

Pre-Market

2.34

0.00
0.00%

Fate Therapeutics, Inc. Profile

About

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.

Info & Links

CEO

Bahram Valamehr

Headquarters

12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA 92131, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.fatetherapeutics.com

Auditor

Ernst & Young, LLP

Share holders

15

Employees

161

Fate Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization2

280.38M

Enterprise Value

247.95M

Enterprise Value/EBITDA(ttm)

-1.99

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

42.64

Price to Book(mrq)

1.75

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1941.09%

Profit Margin(ttm)

-2017.15%

Return on Equity(ttm)

-65.08%

Return on Invested Capital(ttm)

-66.43%

Return on Assets(ttm)

-41.73%

Income Statement

Revenue(ttm)

6.49M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

6.49M

EBITDA(ttm)3

-124.83M

Net Income Available to Common(ttm)

-126.00M

Diluted EPS(ttm)

-1.05

Share Statistics

Beta (5Y Monthly)

2.54

52-Week Change

142.97%

S&P 500 52-Week Change

18.15%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

119.82M

Dividend Yield

0.00%

Float4

114.14M

% Held by Insiders

4.74%

% Held by Institutions

97.54%

Balance Sheet

Total Cash(mrq)

153.77M

Total Cash Per Share(mrq)

1.28

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

4.85%

Quick Ratio(mrq)

4.85%

Book Value Per Share(mrq)

1.31

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.45

Free Cash Flow(ytd)

-54.58M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement